Stutz Charles C, Zhang Xiaobin, Shusta Eric V
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, 1415 Engineering Drive, Madison, WI 53706, USA.
Curr Pharm Des. 2014;20(10):1564-76. doi: 10.2174/13816128113199990459.
The blood-brain barrier (BBB) represents a large obstacle for the treatment of central nervous system diseases. Targeting endogenous nutrient transporters that transcytose the BBB is one promising approach to selectively and noninvasively deliver a drug payload to the brain. The main limitations of the currently employed transcytosing receptors are their ubiquitous expression in the peripheral vasculature and the inherent low levels of transcytosis mediated by such systems. In this review, approaches designed to increase the repertoire of transcytosing receptors which can be targeted for the purpose of drug delivery are discussed. In particular, combinatorial protein libraries can be screened on BBB cells in vitro or in vivo to isolate targeting peptides or antibodies that can trigger transcytosis. Once these targeting reagents are discovered, the cognate BBB transcytosis system can be identified using techniques such as expression cloning or immunoprecipitation coupled with mass spectrometry. Continued technological advances in BBB genomics and proteomics, membrane protein manipulation, and in vitro BBB technology promise to further advance the capability to identify and optimize peptides and antibodies capable of mediating drug transport across the BBB.
血脑屏障(BBB)是治疗中枢神经系统疾病的一大障碍。靶向转运穿过血脑屏障的内源性营养转运体是一种有前景的方法,可选择性且无创地将药物输送至大脑。当前所采用的跨细胞转运受体的主要局限性在于它们在外周血管系统中普遍表达,以及此类系统介导的跨细胞转运固有水平较低。在本综述中,讨论了旨在增加可用于药物递送目的的跨细胞转运受体种类的方法。特别是,可以在体外或体内对血脑屏障细胞筛选组合蛋白质文库,以分离能够触发跨细胞转运的靶向肽或抗体。一旦发现这些靶向试剂,可使用诸如表达克隆或免疫沉淀结合质谱分析等技术来鉴定相关的血脑屏障跨细胞转运系统。血脑屏障基因组学和蛋白质组学、膜蛋白操作以及体外血脑屏障技术的持续技术进步有望进一步提升识别和优化能够介导药物跨血脑屏障转运的肽和抗体的能力。